Angiotensin II Blockade and Inflammation in Obesity (ARB)
Overweight, Obese, Prehypertension
About this trial
This is an interventional prevention trial for Overweight focused on measuring angiotensin II, obesity, diabetes
Eligibility Criteria
Inclusion Criteria:
- 18-75 years of age
- Weight stable for previous 6 months (+2.0kg)
- Sedentary to recreationally active
- Willing to be randomized to treatment or placebo
- Verbal and written informed consent
- Approved for participation by Medical Director (Jose Rivero, M.D.)
Exclusion Criteria:
- Blood pressure outside stated range
- Diabetes or taking diabetes medications
- Total cholesterol >6.2 mmol/L; triglycerides >4.5 mmol/L
- Past or current ischemic heart disease, stroke, respiratory disease, endocrine or metabolic disease, neurological disease, or hematological-oncological disease
- Evidence of renal insufficiency; GFR< 60 ml/min*
- Medications (including but not limited to antihypertensives, statins or other with anti-inflammatory actions) or antioxidant vitamins or supplements
- Known allergy or hypersensitivity to olmesartan or any of its components
- Pregnant or planning to become pregnant
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Olmesartan Medoxomil first, then No Drug
No Drug first, then Olmesartan Medoxomil
During the First Intervention (8 weeks), subjects will be provided with daily 20 mg of olmesartan for the first 2 weeks. Subjects receive additional daily doses of 40 mg olmesartan for the remainder of the study period (6 weeks). The dose remains at 20 mg per day, however, if BP falls below 110/70 during the first 2 weeks. In addition, subjects will continue taking the drug during the 2-week follow-up testing period. Subjects will then proceed to the Washout period (2 weeks). During the Second Intervention (8 weeks), no drug will be administered to the subjects.
During the First Intervention (8 weeks), no drug will be administered to the subjects. Subjects will then proceed to the Washout period (2 weeks). During the Second Intervention (8 weeks), subjects will be provided with daily 20 mg of olmesartan for the first 2 weeks. Subjects then receive daily doses of 40 mg olmesartan for the remainder of the study period (6 weeks). The dose remains at 20 mg per day, however, if BP falls below 110/70 during the first 2 weeks. In addition, subjects will continue taking the drug during the 2-week follow-up testing period.